143 related articles for article (PubMed ID: 37086018)
1. B7-H3 drives immunosuppression and Co-targeting with CD47 is a new therapeutic strategy in β-catenin activated melanomas.
Hsu M; Martin TC; Vyas NS; Desman G; Mendelson K; Horst B; Parsons RE; Celebi JT
Pigment Cell Melanoma Res; 2023 Sep; 36(5):407-415. PubMed ID: 37086018
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
[TBL] [Abstract][Full Text] [Related]
3. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
4. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
5. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
[TBL] [Abstract][Full Text] [Related]
6. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract][Full Text] [Related]
7. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
8. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
11. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
14. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
16. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
17. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
18. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T
Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560
[TBL] [Abstract][Full Text] [Related]
19. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]